All | dcSSc | lcSSc | p | |
---|---|---|---|---|
Patients, n | 599 | 165 | 434 | |
Male, % | 16 | 22 | 14 | 0.01 |
Age, yrs | 55 ± 13 | 53 ± 13 | 55 ± 13 | 0.10 |
Occupational risks*, % | 11 | 13 | 10 | 0.23 |
Delay between RP onset and first non-RP clinical symptom, yrs | 6 ± 9 | 3 ± 6 | 7 ± 10 | < 0.0001 |
Time since first non-RP symptom onset, yrs | 7 ± 7 | 8 ± 7 | 7 ± 7 | 0.09 |
Age at first non-RP symptom, yrs | 46 ± 14 | 44 ± 14 | 47 ± 14 | 0.008 |
Never smoker, % | 68 | 67 | 69 | 0.64 |
Current smoker, % | 12 | 15 | 11 | 0.24 |
Tobacco consumption (pack/yr)† | 5 ± 12 | 6 ± 16 | 5 ± 10 | 0.18 |
Rodnan score | 13 ± 11 | 26 ± 12 | 9 ± 5 | < 0.0001 |
Digital sclerosis score | 7 ± 3 | 9 ± 3 | 6 ± 3 | < 0.0001 |
TLC < 80% predicted, % | 15 | 23 | 12 | < 0.0001 |
FVC < 80% predicted, % | 13 | 24 | 8 | < 0.0001 |
DLCO < 60% predicted, % | 24 | 39 | 19 | < 0.0001 |
↵* Exposure to silicates, solvents, glue, or resin.
↵† Never-smokers assigned a consumption of zero. RP: Raynaud’s phenomenon; dcSSc: diffuse cutaneous systemic sclerosis; DLCO: lung diffusing capacity for carbon monoxide; lcSSc: limited cutaneous systemic sclerosis; TLC: total lung capacity; FVC: forced vital capacity.